去甲斑蝥素-泊洛沙姆407缓释制剂局部注射治疗原发性肝癌25例

25 CASES OF PRIMARY LIVER CANCER TREATED BY NORCANTHARIDIN POLOXAMER 407 IN INTRATUMORAL ADMINISTRATION

目的:探讨去甲斑蝥素泊洛沙姆407缓释制剂局部注射治疗肝癌的疗效。方法:选择25例原发性肝癌患者B超引导下经皮肝穿刺瘤内注射去甲斑蝥素泊洛沙姆407缓释制剂治疗,并与29例肝动脉化疗栓塞治疗作疗效对照。结果:两组在抑制肿瘤生长、降低AFP水平和延长生存期等方面并无差别(P>0.05),而去甲斑蝥素泊洛沙姆407缓释制剂局部注射治疗肝癌在提高生存质量上优于肝动脉化疗栓塞治疗。结论:去甲斑蝥素泊洛沙姆407局部注射治疗肝癌确有一定疗效。

Objective:To determine the therapeutic effects of Norcantharidin Poloxamer 407 in intratumoral administration to primary liver cancer.Method:Norcantharidin Poloxamer 407 was injected in 25 cases primary liver cancer panients under Bultrasonic,their therapeutic effects was compared with another 29 patients who were accepted Transcatheter Arterial Chemoembolization.Result:There is no different of Norcantharidin Poloxamer 407 intratumoral administration and Transcatheter Arterial Chemoembolization in restrain tumor growth,reduce serum AFP and prolong survival (P>0.05),but who are treated with Norcantharidin Poloxamer407 had higher quality of life.Conclusion:Norcantharidin Poloxamer 407 is an effective drug for using in intratumorl administration.